Status:
COMPLETED
Energy for Lymphocytes
Lead Sponsor:
Hôpital Cochin
Collaborating Sponsors:
Assistance Publique - Hôpitaux de Paris
Conditions:
Non-small Cell Lung Cancer
Progression, Disease
Eligibility:
All Genders
18+ years
Brief Summary
CERTIM is a cohort created in July 2015 to set up a multidisciplinary follow-up of cancer patients treated with immune checkpoint inhibitors. From the CERTIM cohort, we conducted a longitudinal, pros...
Eligibility Criteria
Inclusion
- 18 years or older
- Stage IV histologically proven Non Small Cell Lung Cancer (NSCLC)
- Monotherapy with nivolumab or pembrolizumab.
- Patients were required to have measurable disease per the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.
Exclusion
- Active malignancy other than NSCLC,
- ALK or EGFR mutated NSCLC
- Anticancer therapy or surgery within the past 2 weeks or inability to breathe under the calorimetry.
Key Trial Info
Start Date :
August 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 30 2020
Estimated Enrollment :
144 Patients enrolled
Trial Details
Trial ID
NCT04879316
Start Date
August 1 2016
End Date
April 30 2020
Last Update
May 12 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cochin Hospital
Paris, France, 75014